The relevance of CYP2D6 genetic polymorphism on chronic metoprolol therapy in cardiovascular patients

Journal of Clinical Pharmacy and Therapeutics

Volumn 31, Issue 1, 2006, Pages 99-109

  Ismail, R ^a   Teh, L K ^b  

^a INSTITUTE FOR RESEARCH IN MOLECULAR MEDICINE INFORMM   (Malaysia)

^b UNIVERSITI TEKNOLOGI MARA   (Malaysia)

Author keywords

Cardiovascular; CYP2D6; Metoprolol; Plasma metabolic ratio

Indexed keywords

ALPHA HYDROXYMETOPROLOL; CYTOCHROME P450 2D6; DNA; METOPROLOL;

ADULT; AGED; ARTICLE; CARDIOVASCULAR DISEASE; CHRONIC DRUG ADMINISTRATION; CONTROLLED STUDY; DNA EXTRACTION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DOSE REGIMEN; DRUG METABOLISM; ENZYME ACTIVITY; GENE DUPLICATION; GENETIC CORRELATION; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE; HEART MUSCLE ISCHEMIA; HOMOZYGOSITY; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; PHARMACOGENOMICS; PLASMA CLEARANCE; PREDICTION; SAMPLE SIZE; STEADY STATE;

ADULT; AGED; AGED, 80 AND OVER; ANTI-ARRHYTHMIA AGENTS; ANTIHYPERTENSIVE AGENTS; CARDIOVASCULAR DISEASES; CYTOCHROME P-450 CYP2D6; FEMALE; GENOTYPE; HUMANS; KIDNEY DISEASES; MALE; METOPROLOL; MIDDLE AGED; PHARMACOGENETICS; POLYMORPHISM, GENETIC;

EID: 33645113878     PISSN: 02694727     EISSN: 13652710     Source Type: Journal    
DOI: 10.1111/j.1365-2710.2006.00699.x     Document Type: Article

References (24)

1. Horai Y Taga J Ishizaki T Ishikawa K 1990 Correlations among the metabolic ratios of three test probes (metoprolol, debrisoquine and sparteine) for genetically determined oxidation polymorphism in a Japanese population British Journal of Clinical Pharmacology 29 111 115
2. Teh LK Ismail R Yusof R Hussein A Isa MN Rahman AR 2001 Heterogeneity of the CYP2D6 gene among Malays in Malaysia Journal of Clinical Pharmacy and therapeutics 26 205 211
3. Lennard MS Tucker GT Silas JH Freestone S Ramsay LE Woods HF 1983 Differential stereoselective metabolism of metoprolol in extensive and poor debrisoquine metabolizers Clinical Pharmacology and therapeutics 34 732 737
4. Benet LZ Kroetz DL Sheiner LB 1996 Pharmacokinetics In: Hardman LG Goodman Gilman A Limbird LL eds Goodman and Gilman's The pharmacological basis of therapeutics 9th edn New York McGraw-Hill 3 28
5. Jacqz E Hall SD Branch RA 1986 Genetically determined polymorphisms in drug oxidation Hepatology 6 1020 1032
6. Beard K 1992 Adverse reactions as a cause of hospital admission in the aged Drugs and Aging 2 356 367
7. Thum T Borlak J 2000 Gene expression in distinct regions of the heart Lancet 355 979 983
8. Cockcroft DW Gault MH 1976 Prediction of creatinine clearance from serum creatinine Nephron 16 31
9. Johnsson G Regardh CG 1976 Clinical pharmacokinetics of beta-adrenoreceptor blocking drugs Clinical Pharmacokinetics 1 233 263
10. Melander A Danielson K Schersten B Wahlin E 1977 Enhancement of the bioavailability of propanolol and metoprolol by food Clinical Pharmacology and therapeutics 22 108 112
11. Iyun AO Lennard MS Tucker GT Wood HF 1986 Metoprolol and debrisoquine metabolism in Nigerians: lack of evidence for polymorphic oxidation Clinical Pharmacology and therapeutics 40 387 394
12. Grainger SL John VA Shotton PA Smith SE 1985 A multiple dose pharmacokinetic and pharmacodynamic evaluation of conventional and 19/285 Oros formulations of metoprolol in healthy volunteers British Journal of Clinical Pharmacology 19 Suppl. 2 239S 244S
13. Kendall MJ Jack DB Woods KL Laugher SJ Quarterman CP John VA 1982 Comparison of the pharmacodynamic and pharmacokinetic profiles of single and multiple doses of a commercial slow-release metoprolol formulation with a new Oros delivery system British Journal of Clinical Pharmacology 13 393 398
14. McLean AJ McNamara PJ du Souich P Gibaldi M Lalka D 1978 Food, splanchnic blood flow, and bioavailability of drugs subject to first-pass metabolism Clinical Pharmacology and therapeutics 24 5 10
15. Sindrup SH Brosen K Gram LF et al. 1992 The relationship between paroxetine and the sparteine oxidation polymorphism Clinical Pharmacology and therapeutics 51 278 287
16. Castleden CM Kaye CM Parsons RL 1975 The effect of age on plasma levels of propranolol and practolol in man British Journal of Clinical Pharmacology 2 303 306
17. Vestal RE Wood AJ Branch RA Shand DG Wilkinson GR 1979 Effect of age and cigarette smoking on propanolol disposition Clinical Pharmacology and therapeutics 26 8 15
18. Zhou HH Anthony LB Roden DM Wood AJ 1990 Quinidine reduces clearance of (+)-propranolol more than (-)-propranolol through marked reduction in 4-hydroxylation Clinical Pharmacology and therapeutics 47 686 693
19. Lennard MS Silas JH Freestone S Ramsay LE Tucker GT Woods HF 1982 Oxidation phenotype - a major determinant of metoprolol metabolism and response New England Journal of Medicine 307 1558 1560
20. Lennard MS Silas JH Freestone S Trevethick J 1982 Defective metabolism of metoprolol in poor hydroxylators of debrisoquine British Journal of Clinical Pharmacology 14 301 303
21. McGourty JC Silas JH Lennard MS Tucker GT Woods HF 1985 Metoprolol metabolism and debrisoquine oxidation polymorphism - population and family studies British Journal of Clinical Pharmacology 20 555 566
22. Huang JD Chuang SK Cheng CL Lai ML 1999 Pharmacokinetics of metoprolol enantiomers in Chinese subjects of major CYP2D6 genotypes Clinical Pharmacology and therapeutics 65 402 407
23. Leblond FA Giroux L Villeneuve JP Pichette V 2000 Decreased in vivo metabolism of drugs in chronic renal failure Drug Metabolism and Disposition 28 1317 1320
24. Rostami-Hodjegan A Funckbrentano C Kroemer H Tucker GT 1999 In vivo indices of enzyme activity, the effect of renal impairment on the assessment of CYP2D6 activity Pharmacogenetics 9 277 286